Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

被引：14
|
作者：
Leal, Ticiana A. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期
关键词：
CHEMOTHERAPY;
D O I：
10.1016/j.xcrm.2022.100691
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
    Pai-Scherf, Lee
    Blumenthal, Gideon M.
    Li, Hongshan
    Subramaniam, Sriram
    Mishra-Kalyani, Pallavi S.
    He, Kun
    Zhao, Hong
    Yu, Jingyu
    Paciga, Mark
    Goldberg, Kirsten B.
    Mckee, Amy E.
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2017, 22 (11): : 1392 - 1399
  • [32] FDA drug approval summary:: Pemetrexed for injection (Alimta®) for the treatment of non-small cell lung cancer
    Cohen, MH
    Johnson, JR
    Wang, YC
    Sridhara, R
    Pazdur, R
    ONCOLOGIST, 2005, 10 (06): : 363 - 368
  • [33] PATTERNS IN IMMUNOTHERAPY UTILIZATION FOR NON-SMALL CELL LUNG CANCER PRE- AND POST-FDA APPROVAL
    Olateju, O. A.
    Zhen, Z.
    Sujit, S. S.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2023, 19 (03): : 565 - 565
  • [34] Neoadjuvant Therapy with Immune Checkpoint Inhibitors in operable non-small cell Lung Cancer
    Hekmat, Khosro
    Bruns, Christiane J.
    CHIRURG, 2021, 92 (08): : 735 - 735
  • [35] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [36] Neoadjuvant therapy and surgical resection for locally advanced non-small cell lung cancer
    Meko, J
    Rusch, VW
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (04) : 324 - 332
  • [37] Grading of tumor regression in non-small cell lung cancer after neoadjuvant therapy
    Junker, K
    Thomas, M
    Schulmann, K
    Klinke, V
    Bosse, U
    Muller, KM
    PATHOLOGE, 1997, 18 (02): : 131 - 140
  • [38] Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
    Hu, Yan
    Ren, Siying
    Yang, Lulu
    Tong, Zhongyi
    Wang, Ruoyao
    Han, Wei
    Zeng, Chao
    Li, Jina
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Neoadjuvant Intratumoral Immuno-Gene Therapy for Non-Small Cell Lung Cancer
    Predina, Jarrod D.
    Keating, Jane
    Venegas, Ollin
    Nims, Sarah
    Singhal, Sunil
    DISCOVERY MEDICINE, 2016, 21 (116) : 275 - 281
  • [40] Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
    Zhang, Zhenyang
    Lin, Jiangbo
    Kang, Mingqiang
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 1151 - 1153
12345